Treatment of viral and neoplastic diseases with double-stranded RNA derivatives and other new agents

Experimental Biology and Medicine

Volumn 231, Issue 8, 2006, Pages 1283-1286

  Ambrus Sr , Julian L ^a   Chadha, Kailash C ^b   Islam, Anwarul ^a   Akhter, Selina ^a   Ambrus Jr , Julian L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

2 deoxyoligocytidilates; AIDS; Double stranded and single stranded RNA; HIV infection; Neoplastic diseases; Telomerase inhibitors; Thiolated polyi:polyC (pl:MPC); Viral diseases

Indexed keywords

2' DEOXYOLIGOCYTIDILATE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DOUBLE STRANDED RNA; DOUBLE STRANDED RNA DERIVATIVE; MICRORNA; POLYINOSINIC POLYCYTIDYLIC ACID; RNA DERIVATIVE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER INHIBITION; DRUG INHIBITION; HUMAN; NEOPLASM; NONHUMAN; RNA INTERFERENCE; SHORT SURVEY; VIRUS INFECTION;

EID: 33748297497     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100801     Document Type: Short Survey

References (43)

1. O'Donnell KA, Wentzel EA, Zeller KI, Dans CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-843, 2005.
2. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb, J, Peck D, Sweet-Grdero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 435:834-838, 2005.
3. He L, Thompson JM, Hemann MT, Hernando-Mange E, Mu D, Goodson S, Powers S. A microRNA polycistron as potential human oncogene. Nature 435:828-833, 2005.
4. Meltzer PS. Cancer genomics: small RNAs with big impacts [news]. Nature 435:745-746, 2005.
5. Hampton T. MicroRNAs move into cancer research [news]. JAMA 294:411-412, 2005.
6. Bartel DP. MicroRNAs: genetics, biogenesis, mechanism, and function. Cell 116:281-297, 2004.
7. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64:3087-3095, 2004.
8. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell 120:635-647, 2005.
9. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1:882-891, 2003.
10. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 529:122-125, 2002.
11. Haines DS, Strauss KI, Gillespie DH. Cellular response to double-stranded RNA. J Cell Biochem 46:9-20, 1991.
12. Torrence PF, DeClereq E. Interferon inducers: general surgery and classification. Methods Enzymol 78:291-299, 1981.
13. DeClereq E. Synthetic interferon inducers. Top Curr Chem 52:173-203, 1974.
14. Sen GC, Taira H, Lengyel P. Interferon, double-stranded RNA, and protein phosphorylation: characteristics of a double-stranded RNA-activated protein kinase system partially purified from interferon treated Ehrlich ascites tumor cells. J Biol Chem 253:5915-5921, 1978.
15. Levy HB. Interferon and interferon inducers, I: the treatment of malignancies. Arch Intern Med 126:78-83, 1970.
16. Levy HB, Law LW, Rabson AS. Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A 62:357-361, 1969.
17. Bucur N, Mizuno M, Wakabayashi T, Yoshida J. Growth inhibition of experimental glioma by human interferon-β superinduced by cationic liposomes entrapping polyinosilic:polycytidylic acid. Neurol Med Chir (Tokyo) 38:469-474, 1998.
18. Stebbing N, Grantham, CA. Anti-viral activity against encephalomyocarditis virus and Semliki Forest virus and acute toxicity of poly I and poly C administered sequentially to mice. Arch Virol 51:199-215, 1976.
19. Bardos TJ, Aradi J, Ho YK, Halman TI. Biochemical properties of 5-sulfur-substituted pyrimidine nucleosides and nucleotides. Ann N Y Acad Sci 255:522-531, 1975.
20. Bardos TJ, Novak P, Chakrabati P, Ho YK. Partially thiolated polycytidylic acid. In: Townsend LB, Tipson RS, Eds. Nucleic Acid Chemistry. New York: J Wiley & Sons Inc, pp881-884, 1978.
21. O'Malley JA, Hu YK, Chakrabarti P, DiBerardino L, Chandra P, Orinda DA, Byrd DM, Bardos TJ, Carter WA. Antiviral activity of partially thiolated polynucleotides. Mol Pharmacol 11:61-69, 1975.
22. Vastola KA, Ho YK, Bardos TJ, Grossmayer BJ, Fruck-Diviak L, O'Malley JA. Poly I-mercapto poly C: antiviral, anticellular, and pharmacologic effects. Res Commun Chem Pathol Pharmacol 45:407-419, 1984.
23. Bardos TJ, Schinazi, RF, Ling KH, Helder AR. Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1. Antimicrob Agents Chemother 36:108-114, 1992.
24. Cavanaugh PF Jr, Ho YK, Hughes RG Jr, Bardos TJ. Selectivity of antitemplates as inhibitors of deoxyribonucleic acid polymerases. Biochem Pharmacol 31:4055-4060, 1982.
25. Chadha KC, Dembinski WE, Dunn CB, Aradi J, Bardos TJ, Dunn JA, Ambrus JL Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly I:poly C on the α, β and γ interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res 64:171-177, 2004.
26. Kung MP, Ho YK, Bardos TJ. Action of partially thiolated polynucleotides on the DNA polymerase alpha from regenerating rat liver. Cancer Res 36:4537-4542, 1976.
27. Heider AR, Bardos TJ. Oligonucleotides and polynucleotides as potential cancer chemotherapeutic agents. In: Foye WO, Ed. Cancer Chemotherapeutic Agents. Washington: American Chemical Society, pp526-575, 1996.
28. Milkulski AJ, Bardos TJ, Chakrabarti P, Kalman TI, Zsindely A. Inhibition of DNA-dependent RNA polymerase with partially thiolated polynucleotides. Biochem Biophys Acta 319:294-303, 1973.
29. Horvath A, Aradi J. Advantages of sodium perchlorate solution as mobile phase for purification of synthetic oligonucleotides by anion exchange chromatography. Anal Biochem 338:341-343, 2005.
30. Chadha KC, Stadler I, Ambrus JL, Nair MPN. Effect of alcohol and MAIDS virus infection upon immunological status in C57BL/6 mice. Recent Res Dev Immunol 2:41-51, 2000.
31. Stadler I, Chadha KC, Nakeeb S, Toumbis C, Butsch J, Mathur N, Munschauer F, Vladutiu A, Satchidanand SK, Ambrus JL. Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. J Pharmacol Exp Ther 268:10-13, 1994.
32. Chadha KC, Ambrus JL Jr, Dembinski W, Ambrus JL Sr. Interferons and interferon inhibitory activity in disease and therapy. Exp Biol Med 229:285-290, 2004.
33. 35: A novel, highly potent oligonucleotide inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. FEBS Lett 396:43-46, 1996.
34. 35. Virology 334:214-223, 2005.
35. Szatmari I, Tokes S, Dunn C, Bardos TJ, Aradi J. Modified telomeric repeat amplification protocol: a quantitative radioactive assay for telomerase without using electrophoresis. Anal Biochem 282:80-88, 2000.
36. Tarkanyi I, Horvath A, Szatmari I, Eizert H, Vamosi G, Damjanovich S, Segal-Bendirdjian E, Aradi J. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett 579:1411-1416, 2005.
37. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529, 1989.
38. Kelleher C, Teixeira MT, Forstemann K, Lingner J. Telomerase: biochemical considerations for enzyme and substrate. Trends Biochem Sci 27:572-579, 2002.
39. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Covielo GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
40. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 99:12606-12611, 2002.
41. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 30:839-865, 2002.
42. Matthes E, Lehmann C. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res 27:1152-1158, 1999.
43. Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, Segal-Bendirdjian E. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 19:1806-1811, 2005.